LONDON, Feb. 7, 2023
/PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the
"Company") (Nasdaq: VRAX), an innovative diagnostics company
focused on the prevention, detection, and diagnosis of viral
diseases, announced that it has signed a Purchase Order with Cosmos
Health (Nasdaq: COSM) ("Cosmos") to launch and market COVID-19 and
Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to their
previously signed distribution agreement dated September 2022, Cosmos will have exclusive
distribution rights for Greece and
Cyprus, with the opportunity to
distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.
Virax's Chairman of the Board of Directors and Chief Executive
Officer, Mr. James Foster,
commented, "COVID-19, Influenza A and Influenza B are major sources
of illness and mortality in humans across the globe. We are pleased
to offer a dual solution, that can accurately identify infections
related to these viruses, with results typically available in 15
minutes, and improve health outcomes through early
identification."
"COVID-19 continues to threaten lives across the world.
According to the World Health Organization ("WHO"), as of
February 2, 2023, there have been
approximately 750 million confirmed COVID-19 cases and about 7
million COVID-19-attributable deaths,"1 said Mr.
Greg Siokas, Chief Executive Officer
of Cosmos. "While the threat of Influenza has been overshadowed by
COVID-19, the healthcare burden of Influenza should not be
overlooked. WHO reports that Influenza infections result in roughly
5 million cases of severe illness and approximately 650,000
respiratory deaths worldwide each year.2 Therefore, we
are excited to partner with Virax to bring much needed dual testing
solutions to Greece and
Cyprus as well as expanding into
additional territories going forward."
The COVID-19 & Influenza A+B antigen combo rapid test is a
single-use test kit intended for qualitative detection of
nucleocapsid protein antigen of Influenza A and B viral antigens
and COVID-19 antigen from nasal swab specimens.
About Virax Biolabs Group Limited
Founded in 2013, Virax Biolabs Group Limited is an innovative
diagnostics company focused on the prevention, detection and
diagnosis of viral diseases, with a particular interest in the
field of immunology.
In addition to distributing an array of viral test kits in
unique geographies, Virax Biolabs Group Limited is currently
developing a proprietary T-Cell Test technology with the intention
of providing an immunology profiling platform that assesses each
individual's immune risk profile against major global viral
threats. T-Cell testing can be particularly effective in the
diagnosis and therapeutics of COVID-19 as well as other threats
including Monkeypox, Hepatitis B, Malaria, Herpes and Human
Papillomavirus. For more information, please visit
www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March
31, 2022. Although we believe the expectations reflected in
such forward-looking statements are reasonable, we can give no
assurance that such expectations will prove to be correct. We are
not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
1 WHO Coronavirus (COVID-19) Dashboard. (n.d.). With
Vaccination Data. https://covid19.who.int/
2 Influenza (Seasonal). (2023, January 12).
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-group-limited-announces-purchase-order-to-launch-covid-19-and-influenza-ab-antigen-combo-rapid-tests-with-cosmos-health-nasdaqcosm-301740701.html
SOURCE Virax Biolabs